TerminatedPhase 1

Clinical Trial of Nebulized Hypertonic Saline to Attenuate Post-Traumatic Acute Lung Injury

Stopped: low enrollment and loss of funding

United States13 participantsStarted 2012-05

Plain-language summary

This study evaluates the use of nebulized hypertonic saline (aerosolized salt water) as a preventive treatment for post-traumatic acute lung injury (ALI). Both animal and human research indicate that aerosolized salt water might help reduce harmful inflammation with minimal risks.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * adult 18 ≤ age ≤ 65 * trauma with a 9 ≤ NISS ≤ 36 * ≤10 units of RBC in the first 6 hours (as this is a major risk factor for ARDS and MOF in this population) Exclusion Criteria: * Direct or indirect lung injury * Elevated intracranial pressure requiring treatment, including but not limited to mannitol, intravenous hypertonic saline, and ventricular drainage * History of severe chronic respiratory disease * Child-Pugh Class C liver failure * Prisoners * Pregnant women

What they're measuring

change in the respiratory parameters

Timeframe: baseline and every 6 hours for 36 hours

Trial details

NCT IDNCT01667666

SponsorDenver Health and Hospital Authority

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-11-06

View on ClinicalTrials.gov More Acute Lung Injury trials